Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Netherlands Swaps Germany For Norway To Set Prices

Industry Claims Move Is Unnecessary And Threatens Access

Executive Summary

The Netherlands will secure lower medicine prices by referencing Norway instead of Germany to set maximum prices. 

You may also be interested in...



Dutch Heath Minister Accused Of Polarizing Medicine Price Debate

Dutch Health Minister Bruno Bruins has attacked pharmaceutical companies over their drug pricing practices, and has threatened to name and shame one particular firm.

Dutch Move On Pharmacy Compounding Could Deter Orphan Drug Launches

Medicines prepared in pharmacies are now exempt from patent law in the Netherlands, giving pharmacists greater scope to prepare their own versions of patented medicines.

What’s Next After 20 Years Of NICE?

Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.

Topics

UsernamePublicRestriction

Register

PS141456

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel